Prognosis according to histochemical analysis of liver metastases removed at liver resection

British Journal of Surgery

Volumn 101, Issue 13, 2014, Pages 1681-1691

  Brunner, S M ^a   Kesselring, R ^a   Rubner, C ^a   Martin, M ^a   Jeiter, T ^a   Boerner, T ^a   Ruemmele, P ^a   Schlitt, H J ^a   Fichtner Feigl, S ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; TUMOR MARKER;

AGED; COLORECTAL TUMOR; FEMALE; FIBROSIS; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SECONDARY; TUMOR MICROENVIRONMENT;

AGED; ANTIGENS, CD4; ANTIGENS, CD8; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FIBROSIS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84909584637     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9627     Document Type: Article

References (33)

1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
2. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10: 1.
3. Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 2011; 33: 335-340.
4. Camus M, Tosolini M, Mlecnik B, Pagès F, Kirilovsky A, Berger A et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69: 2685-2693.
5. Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D et al. Immune infiltration in human cancer: prognostic significance and disease control. Curr To p Microbiol Immunol 2011; 344: 1-24.
6. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
7. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.
8. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-618.
9. Pagès F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 2008; 84: 981-987.
10. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666.
11. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29: 1093-1102.
12. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-5951.
13. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-1271.
14. + myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci 2011; 102: 1724-1733.
15. Galon J, Fridman WH, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67: 1883-1886.
16. Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford) 2010; 12: 227-238.
17. Roxburgh CS, Richards CH, Moug SJ, Foulis AK, McMillan DC, Horgan PG. Determinants of short- and long-term outcome in patients undergoing simultaneous resection of colorectal cancer and synchronous colorectal liver metastases. Int J Colorectal Dis 2012; 27: 363-369.
18. Shin SJ, Ahn JB, Choi JS, Choi GH, Lee KY, Baik SH et al. Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer. Surg Oncol 2012; 21: e125-e130.
19. Hill CR, Chagpar RB, Callender GG, Brown RE, Gilbert JE, Martin RC II et al. Recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol 2012; 19: 139-144.
20. Spelt L, Andersson B, Nilsson J, Andersson R. Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review. Eur J Surg Oncol 2012; 38: 16-24.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1). Eur J Cancer 2009; 45: 228-247.
22. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
23. Gulubova MV, Vlaykova TI. Significance of tenascin-C, fibronectin, laminin, collagen IV, alpha5beta1 and alpha9beta1 integrins and fibrotic capsule formation around liver metastases originating from cancers of the digestive tract. Neoplasma 2006; 53: 372-383.
24. Lunevicius R, Nakanishi H, Ito S, Kozaki K, Kato T, Tatematsu M et al. Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. J Cancer Res Clin Oncol 2001; 127: 193-199.
25. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 2004; 91: 327-333.
26. Okano K, Maeba T, Moroguchi A, Ishimura K, Karasawa Y, Izuishi K et al. Lymphocytic infiltration surrounding liver metastases from colorectal cancer. J Surg Oncol 2003; 82: 28-33.
27. Bian EB, Huang C, Wang H, Wu BM, Zhang L, Lv XW et al. DNA methylation: new therapeutic implications for hepatic fibrosis. Cell Signal 2013; 25: 355-358.
28. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
29. Liu Y, Munker S, Müllenbach R, Weng HL. IL-13 signaling in liver fibrogenesis. Front Immunol 2012; 3: 116.
30. Ivanecz A, Potrc S, Horvat M, Jagric T, Gadzijev E. The validity of clinical risk score for patients undergoing liver resection for colorectal metastases. Hepatogastroenterology 2009; 56: 1452-1458.
31. Kobayashi H, Kotake K, Sugihara K. Prognostic scoring system for stage IV colorectal cancer: is the AJCC sub-classification of stage IV colorectal cancer appropriate? Int J Clin Oncol 2013; 18: 696-703.
32. Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ et al. Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg 2008; 393: 13-19.
33. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71: 5670-5677.